Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension
Open Access
- 9 July 2026
- journal article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 68, 101768
Abstract
No abstract availableKeywords
Funding Information
- Biogen
This publication has 26 references indexed in Scilit:
- Continuous indices to assess the phenotypic spectrum of kidney transplant rejectionNature Communications, 2025
- Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft RejectionKidney International Reports, 2025
- A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipientsKidney International, 2025
- Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsiesNature Medicine, 2025
- Clinical utility of donor-derived cell-free DNA testing for kidney transplant monitoring in selected patientsKidney International, 2025
- Microvascular Inflammation of Kidney Allografts and Clinical OutcomesNew England Journal of Medicine, 2025
- Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication systemAmerican Journal of Transplantation, 2024
- A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionNew England Journal of Medicine, 2024
- Cell-free DNA for the detection of kidney allograft rejectionNature Medicine, 2024
- The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnosticsAmerican Journal of Transplantation, 2023